Clinical Trial

Residual Exacerbations With Mepolizumab

Recruiting
View on ClinicalTrials.gov →
Summary
This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2020-10-02; most recent amendment 2025-02-07.
Status change: Not Yet Recruiting → Recruiting 2025-02-07
Trial Details
NCT Number NCT04578171
Lead Sponsor Laval University
Collaborators: GlaxoSmithKline
Conditions Asthma
Enrollment 60 participants
Start Date 2021-07-06
Primary Completion 2027-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-10